Dr. Warren Lo, M.D.
Claim this profileMore about Warren Lo, M.D.
Clinical Trial Related
6 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Warren Lo, M.D. has experience with
- I-ACQUIRE - High Dosage
- I-ACQUIRE - Moderate Dosage
- Usual & Customary Treatment (U&CT)
Breakdown of trials Warren Lo, M.D. has run
Cerebral Palsy
Peripheral Neuropathy
Perinatal Stroke
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Warren Lo, M.D. specialize in?
Warren Lo, M.D. focuses on Cerebral Palsy and Peripheral Neuropathy. In particular, much of their work with Cerebral Palsy has involved treating patients, or patients who are undergoing treatment.
Is Warren Lo, M.D. currently recruiting for clinical trials?
No, Warren Lo, M.D. is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Warren Lo, M.D. has studied deeply?
Yes, Warren Lo, M.D. has studied treatments such as I-ACQUIRE - High Dosage, I-ACQUIRE - Moderate Dosage, Usual & Customary Treatment (U&CT).
What is the best way to schedule an appointment with Warren Lo, M.D.?
Apply for one of the trials that Warren Lo, M.D. is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.